German biotechnology company Bio n Tech is working with New York-based pharmaceutical company Pfizer Inc. to develop a vaccine to prevent coronavirus infection. The two companies are confident of getting regulatory approval to supply the much-awaited vaccine in large quantities by the end of this year.
That’s what Yugur Shahin, CEO of Bio N Tech, told the Wall Street Journal. The Wall Street Journal also now says that the goal set by scientists to bring the vaccine to market this year seems to be achievable.
Bio N Tech says tests on the final or third phase of their vaccine are set to begin later this month. 30,000 people are being included in this test. The results of this test will be known within this year. The organization will then seek approval for the vaccine in various countries around the world.
Meanwhile, in an interview with Time magazine, Pfizer’s chief executive officer (CEO) Albert Borla said the same thing. Borla said they hope to get approval from the Food and Drug Administration for their vaccine by next October. They will know the effectiveness of the vaccine in September.
On July 1, Pfizer said the results of the vaccine were positive. It enhances immunity in healthy people. However, if given in high doses, other side effects including fever occur. The first clinical information on Pfizer’s vaccine was published in the journal MedRXIV. Since the positive results were released, the annual vaccine dose target has been increased to 100 million.
“Once we get the final research results, we will be able to claim success with more emphasis,” Borla said. But I have seen many signs that it will be effective. We will have enough information by next September to say whether the vaccine will be effective. This information will be submitted to the FDA for approval. If we are lucky, we can get the approval next October. It’s possible. ”
The deadly coronavirus has infected more than 12 million people worldwide in the last seven months. More than 5 lakh have died. This means that the company that will be the first in the vaccine race is facing billions of dollars in trade.
